Marizyme, Inc. Stock Other OTC
Equities
GBSX
US5703721028
Biotechnology & Medical Research
Financials (USD)
Sales 2021 | 210K | Sales 2022 | 233K | Capitalization | 21.28M |
---|---|---|---|---|---|
Net income 2021 | -11M | Net income 2022 | -38M | EV / Sales 2021 | 329 x |
Net cash position 2021 | 2.12M | Net Debt 2022 | 4.86M | EV / Sales 2022 | 112 x |
P/E ratio 2021 |
-5.8
x | P/E ratio 2022 |
-0.56
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 67.69% |
Managers | Title | Age | Since |
---|---|---|---|
David Barthel
CEO | Chief Executive Officer | - | 21-11-15 |
George Kovalyov
DFI | Director of Finance/CFO | 39 | 21-12-20 |
Chairman | 70 | 21-02-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Stewart
BRD | Director/Board Member | 66 | 22-05-31 |
David Barthel
CEO | Chief Executive Officer | - | 21-11-15 |
William G. Hearl
BRD | Director/Board Member | 66 | 20-10-29 |
1st Jan change | Capi. | |
---|---|---|
+2.49% | 96.73B | |
-1.86% | 21.31B | |
-16.61% | 21.21B | |
-5.80% | 18.79B | |
-42.14% | 16.37B | |
-27.40% | 13.68B | |
+1.44% | 13.44B | |
+21.29% | 10.98B | |
-21.79% | 8.56B |